STANDAGE Co., Ltd. (Minato-ku, Tokyo; CEO: Akinori Adachi; hereinafter referred to as Standage), which develops and provides digital trade platforms, obtained a pharmaceutical sales license in November 2022. This will further expand the range of products that can be handled through "Digitrad," the trade package for domestic companies provided by Standage.

Standage provides a trade-related packaging service called "Digitrad" to domestic small and medium-sized enterprises that are considering exporting their own products, and in order to expand the range of products it can handle, it is in the process of obtaining the necessary licenses to handle products in each field.

Due to the COVID-19 pandemic, pharmaceutical exports have increased by more than 50% in 2020-21.

Standage also receives inquiries and consultations regarding pharmaceutical exports on a daily basis, and has obtained this license in order to meet these needs.

Although no license is required to export pharmaceuticals, the newly acquired "Pharmaceutical Sales Permit" is required to handle pharmaceuticals within Japan, including purchasing from domestic manufacturers.

With this license, Standage aims to further contribute to the expansion of Japan's exports by expanding the range of products it can handle.